Leo Cancer Care, a company that’s pushing the boundaries in cancer treatment technology, has recently completed a funding round that raised about $40 million. This round was led by Catalio Capital Management and included both new and returning investors. The funds will help the company move faster in bringing its next-generation upright radiotherapy system to market. This system is built to enhance patient results and make advanced cancer treatments more available to people everywhere. As part of the deal, Dr. Nicholas von Guionneau from Catalio will join the company’s board as an observer.
Health Technology Insights: Sunflower Therapeutics Gets First Milestone Payment from SK Bioscience
Stephen Towe, Co-Founder and CEO of Leo Cancer Care, expressed excitement about Catalio joining the team and thanked the support from both new and existing investors. He pointed out that this support shows increasing belief in the advantages of upright radiotherapy, particularly in improving the patient experience and making care more accessible globally. Towe also mentioned that the company is focused on creating solutions that offer more comfort and efficiency in cancer treatment while maintaining high clinical standards.
Dr. Nicholas von Guionneau shared his excitement about the investment, highlighting that Leo Cancer Care has developed an innovative technology platform centered around upright patient positioning. He explained that this approach opens up new possibilities for both therapeutic and diagnostic advancements. He also noted that Catalio is proud to back Leo’s mission as the company grows in the proton therapy field and gets ready to enter the photon therapy market.
Health Technology Insights: Commence and The Language Group Launch Fetch for Better Patient Care
Leo Cancer Care’s main product, Marie, is named after the scientist Marie Curie. It’s an upright positioning system combined with a CT scanner, specifically designed for proton therapy. Instead of rotating a large and expensive gantry around the patient, Marie lets the patient rotate, which lowers the size, cost, and complexity of proton therapy. This makes the technology more practical for treatment centers and more comfortable for patients.
Marie recently received 510(k) clearance from the U.S. Food and Drug Administration, and several top cancer centers in the U.S. have already installed the system. The first patient treatments using Marie are planned to start in 2025. Leo Cancer Care is also set to introduce a new photon therapy system later this month at the ASTRO annual meeting, the largest radiotherapy conference in the world. The event will also highlight the company’s growing commercial success through new partnerships and several system orders.
Health Technology Insights: Exxat Partners with Therapy Partner Solutions to Boost Clinical Education
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
